201 filings
6-K
BDRX
Biodexa Pharmaceuticals Plc
19 Apr 24
Preliminary Results for the Year Ended 31 December 2023
8:19am
6-K
BDRX
Biodexa Pharmaceuticals Plc
23 Feb 24
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
1:25pm
6-K
BDRX
Biodexa Pharmaceuticals Plc
22 Jan 24
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
8:51am
6-K
BDRX
Biodexa Pharmaceuticals Plc
29 Dec 23
Biodexa Appoints Ann Merchant to the Board of Directors
12:10pm
6-K
BDRX
Biodexa Pharmaceuticals Plc
21 Dec 23
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
4:30pm
6-K
smw3z
6 Dec 23
Current report (foreign)
4:15pm
6-K
5p7x6ymx
27 Nov 23
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
8:45am
6-K
5532qun0g dd0iaex9i
3 Oct 23
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
10:10am
6-K
xj6l4i
29 Sep 23
Current report (foreign)
4:45pm
6-K
jxa67908cjguln
24 Jul 23
Current report (foreign)
8:07am
6-K
m5j7f9eq
10 Jul 23
Current report (foreign)
8:27am
6-K
tcrxanil 4xin4h4b
6 Jul 23
Results of Appeal of Delisting Determination
4:43pm
6-K
2h88m6qnce1q493 9mae
6 Jul 23
Current report (foreign)
11:52am
6-K
7cxm07
22 Jun 23
Current report (foreign)
4:33pm
6-K
2d61xznr0v7 4tah27n7
20 Jun 23
Current report (foreign)
8:16am
6-K
yppn6nzv du9luhx8
15 Jun 23
Current report (foreign)
4:51pm
6-K
t0q9c5 32x5q
14 Jun 23
Results of Annual General Meeting and General Meeting
8:35am
6-K
rom695cdf8 848
1 Jun 23
Biodexa Pharmaceuticals PLC?Annual Report 2022Biodexa Pharmaceuticals PLC(formerly Midatech Pharma Plc)Annual Report 2022
7:27am
6-K
5v55a2iu8s h9cnv
26 May 23
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
4:24pm
6-K
cyy2dvavpderog4ltdk
24 May 23
Current report (foreign)
5:29pm